Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lung Capacity01:47

Lung Capacity

56.4K
The air in the lungs is measured in volumes and capacities. Lung volume measures reflect the amount of air taken in, released, or left over after a lung function, like a single inhalation. Lung capacity measures are sums of two or more lung volume measures.
56.4K
Cancer Cell Migration through Invadopodia01:35

Cancer Cell Migration through Invadopodia

3.3K
Invadosome is a broad category of cell surface structures with proteolytic activity that  degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...
3.3K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

7.2K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.2K
Pleura of the Lungs01:13

Pleura of the Lungs

7.6K
The lungs are nestled in a cavity, shielded by the pleura. The pleura, a form of serous membrane, wraps around each lung. This membrane arrangement consists of two layers: the visceral and parietal pleurae. The visceral pleura lines the surface of the lungIn contrast, the parietal pleura is the outer layer and contacts to the thoracic wall, the mediastinum, and the diaphragm. The hilum is the point of connection between the visceral and parietal layers. The space between the parietal and...
7.6K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

6.0K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
6.0K
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

15.0K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
15.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of the Hypomethylating Agent Guadecitabine on Peripheral Blood Mononuclear Cell Methylomes and Immune Cell Populations in Small-Cell Lung Cancer Patients.

Pharmaceuticals (Basel, Switzerland)·2026
Same author

Pharmacokinetic Drug-Drug Interaction Potential of Oral Anticancer Drugs.

Clinical pharmacology and therapeutics·2026
Same author

Adverse COVID-19 experiences and physical and psychological outcomes in patients with lung cancer.

Palliative & supportive care·2026
Same author

Effects of the Hypomethylating Agent Guadecitabine on Peripheral Blood Mononuclear Cell Methylomes and Immune Cell Populations in Small-Cell Lung Cancer Patients.

bioRxiv : the preprint server for biology·2026
Same author

Protocol of a randomized trial of acceptance and commitment therapy for patient fatigue interference and caregiver burden in advanced gastrointestinal cancer.

Contemporary clinical trials·2025
Same author

Impact of Histology and PD-L1 Status on Immune Checkpoint Inhibitors in the Treatment of Non-Small Cell Lung Cancer a Systemic Review and Meta-analysis.

Clinical lung cancer·2025
Same journal

Clinical Trials and Translational Advances in Metabolic Targeting.

Cancer treatment and research·2026
Same journal

Tools and Technologies for Studying Cancer Metabolism.

Cancer treatment and research·2026
Same journal

Cancer and Immune Cells: A Metabolic Battle in the Tumor Microenvironment.

Cancer treatment and research·2026
Same journal

Biomarkers of Cancer Metabolism and Therapeutic Response.

Cancer treatment and research·2026
Same journal

Targeting Metabolism in Cancer Therapy: Inhibitors and Approaches.

Cancer treatment and research·2026
Same journal

Metabolic Reprogramming in Cancer Stem Cells.

Cancer treatment and research·2026
See all related articles

Related Experiment Video

Updated: Feb 10, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

424

Small Cell Lung Cancer.

Erica B Bernhardt1, Shadia I Jalal2

  • 1Dartmouth-Hitchcock Medical Center, One Medical Center Drive, Lebanon, NH, 03756, USA.

Cancer Treatment and Research
|August 19, 2016
PubMed
Summary
This summary is machine-generated.

Small cell lung cancer (SCLC) is an aggressive neuroendocrine cancer. Despite initial chemotherapy response, SCLC has a poor prognosis, necessitating novel therapies for improved survival.

Keywords:
ChemotherapyImmune therapyParaneoplastic syndromesProphylactic cranial irradiationRadiationSmall cell lung cancerTargeted therapy

More Related Videos

Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines
09:45

Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines

Published on: August 21, 2019

7.5K
Instillation and Fixation Methods Useful in Mouse Lung Cancer Research
06:57

Instillation and Fixation Methods Useful in Mouse Lung Cancer Research

Published on: August 31, 2015

29.6K

Related Experiment Videos

Last Updated: Feb 10, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

424
Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines
09:45

Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines

Published on: August 21, 2019

7.5K
Instillation and Fixation Methods Useful in Mouse Lung Cancer Research
06:57

Instillation and Fixation Methods Useful in Mouse Lung Cancer Research

Published on: August 31, 2015

29.6K

Area of Science:

  • Oncology
  • Pulmonology
  • Cancer Research

Background:

  • Small cell lung cancer (SCLC) is an aggressive neuroendocrine tumor strongly linked to smoking.
  • SCLC often presents as metastatic disease, posing significant treatment challenges.
  • The disease exhibits heterogeneity with both chemosensitive and chemoresistant clones.

Purpose of the Study:

  • To review the current understanding of SCLC, including its characteristics, staging, and standard treatment approaches.
  • To highlight the limitations of existing therapies and the urgent need for novel treatment strategies.

Main Methods:

  • Literature review of SCLC epidemiology, pathology, and treatment guidelines.
  • Analysis of standard first-line chemotherapy regimens (cisplatin and etoposide) for limited and extensive stage SCLC.
  • Evaluation of the role of radiation therapy, including thoracic radiation and prophylactic cranial irradiation (PCI).

Main Results:

  • SCLC is characterized by rapid progression and poor prognosis despite initial response to chemotherapy.
  • Standard treatment involves combination chemotherapy with cisplatin and etoposide, with radiation therapy playing a role in specific stages.
  • Current therapeutic strategies show limited long-term survival benefits, underscoring the need for new interventions.

Conclusions:

  • SCLC remains a challenging malignancy with a dismal prognosis.
  • Novel therapeutic approaches are critically needed to improve survival rates in SCLC patients.
  • Further research into targeted therapies and innovative treatment combinations is essential.